In conclusion, our preliminary data suggest that EMT could represent a common mechanism among very different colon cancer types and LiCl, a GSK3β inhibitor, induces MET in both cell types despite their genotype, suggesting that LiCl and GSK3β could represent, respectively, interesting drug and target for CRC therapy. The gene discussed is MET; the disease is colorectal carcinoma.